Recent technological advances in dialysis have not been translated into significant improvement in clinical outcomes. Patients on dialysis still exhibit uraemic symptoms, as well as systemic manifestations. Accumulation of larger uraemic toxins may contribute significantly to poor clinical outcomes in haemodialysis patients. Our distinguished faculty will provide delegates with a state-of-the-art update on the toxicity of uraemic solutes, with a focus on large middle molecules. Delegates will also be updated on emerging data linking uraemic inflammation to clinical events, as well as to uraemic solutes. Finally, delegates will be introduced to the concept of expanded haemodialysis (HDx), a new therapy option enabled by recent innovation in membrane design.
Introductions and welcome
Uncovering the unmet need:The scientific rationale Colin Hutchison, New Zealand
Innovation meeting the need Chris McIntyre, Canada
A new therapy: Rise of HDx Claudio Ronco, Italy
Summary and close
Scientific Chair Angelito Bernardo, USA
Faculty Colin Hutchison, New Zealand Chris McIntyre, Canada Claudio Ronco, Italy